L-NAME (hydrochloride)
L-NAME hydrochloride inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM.
Product Specifications
CAS Number
[51298-62-5]
Product Name Alternative
NG-Nitroarginine methyl ester hydrochloride
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
NO Synthase
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/L-NAME-hydrochloride.html
Purity
99.89
Solubility
H2O : 100 mg/mL (ultrasonic)
Smiles
N[C@@H](CCCNC(N[N+]([O-])=O)=N)C(OC)=O.[H]Cl
Molecular Formula
C7H16ClN5O4
Molecular Weight
269.69
Precautions
H302, H315, H319, H335
References & Citations
[1]Pfeiffer S, et al. Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME) : requirement forbioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol. 1996 Jul;118 (6) :1433-40.|[2]Kopincová J, et al. L-NAME in the cardiovascular system - nitric oxide synthase activator? Pharmacol Rep. 2012;64 (3) :511-20.|[3]Lo HC, et al. The Nitric Oxide Synthase Inhibitor NG-Nitro-L-Arginine Methyl Ester Diminishes the Immunomodulatory Effects of Parental Arginine in Rats with Subacute Peritonitis. PLoSOne. 2016 Mar 23;11 (3) :e0151973.|[4]Luo H, et al. Effect of nitric oxide synthase inhibitor L-NAME on fear extinction in rats: a task-dependent effect. Neurosci Lett. 2014 Jun 20;572:13-8.|[5]Ocsan RJ, et al. Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration in C57BL/6J mice induces a sustained decrease in c-kit positive cells during development of cardiac hypertrophy. J Physiol Pharmacol. 2013 Dec;64 (6) :727-36.|[6]V A Peotta, et al. Cardiovascular neural reflexes in L-NAME-induced hypertension in mice. Hypertension. 2001, 38, 3.|[7]Xiaofei Li, et al. Fucoidan from Undaria pinnatifida prevents vascular dysfunction through PI3K/Akt/eNOS-dependent mechanisms in the l-NAME-induced hypertensive rat model. Food Funct. 2016, 7, 5.|[8]de Alwis N, et al. The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health. Life Sci Alliance. 2022 Aug 5;5 (12) :e202201517.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Citation 01
Adv Sci (Weinh) . 2024 Jun;11 (21) :e2309002.|Aging Cell. 2025 Feb 6:e14502.|Aging Cell. 2025 Sep 29:e70222.|Am J Physiol Cell Physiol. 2025 Oct 30.|Arterioscler Thromb Vasc Biol. 2020 Jul;40 (7) :1705-1721.|Bioengineered. 2022 Jan;13 (1) :1320-1334.|Biol Direct. 2024 Nov 26;19 (1) :121.|Biomed Pharmacother. 2019 Jul:115:108934.|Biomed Pharmacother. 2023 May:161:114484.|Biomed Res Int. 2021 May 14:2021:5565748.|bioRxiv. 2023 Dec 4.|bioRxiv. 2023 Nov 1.|bioRxiv. 2025 May 06.|BMC Nephrol. 2024 Jul 15;25 (1) :226.|Bosn J Basic Med Sci. 2017 May 20;17 (2) :132-137.|Brain Dev. 2025 Jul 1;47 (4) :104388.|Cancer Metab. 2024 May 17;12 (1) :14.|Cancer Res. 2024 Jun 14;84 (12) :1963-1977.|Cardiovasc Diabetol. 2024 May 9;23 (1) :164.|Cell Commun Signal. 2021 Mar 18;19 (1) :35.|Chem Biol Interact. 2025 May 28:111577.|Clin Epigenetics. 2025 Nov 19;17 (1) :195.|Clin Exp Pharmacol Physiol. 2025 Nov;52 (11) :e70081.|Commun Biol. 2025 Nov 25;8 (1) :1682.|Evid Based Complement Alternat Med. 2020 Mar 10;2020:3524641.|Exp Anim. 2025 Oct 30.|Exp Ther Med. 2018 Aug;16 (2) :1079-1086.|FASEB J. 2024 Jul 31;38 (14) :e23844.|FASEB J. 2025 Jul 31;39 (14) :e70817.|FASEB J. 2025 Jun 15;39 (11) :e70697.|Free Radic Biol Med. 2024 Sep 13:S0891-5849 (24) 00659-2.|Free Radic Biol Med. 2025 Jul:234:72-85.|Front Cardiovasc Med. 2021 Apr 13:8:654254.|Front Med. 2021 Apr 13:8:634882.|Hum Gene Ther. 2023 Jan;34 (1-2) :42-55.|Insect Mol Biol. 2024 Jun;33 (3) :206-217.|Int Immunopharmacol. 2024 Jan 25:127:111313.|Int Immunopharmacol. 2024 Nov 13;143 (Pt 3) :113617.|Int J Immunopathol Pharmacol. 2022 Jan-Dec:36:3946320221111117.|Int J Med Sci. 2025 Jan 21;22 (4) :920-932. |Int J Mol Med. 2024 Aug;54 (2) :67.|Int J Mol Sci. 2023 Mar 7;24 (6) :5111.|J Cardiovasc Transl Res. 2024 Dec;17 (6) :1415-1426.|J Cell Mol Med. 2024 Apr;28 (8) :1-11.|J Ethnopharmacol. 2022 Oct 5:296:115476.|J Extracell Vesicles. 2023 May;12 (5) :e12328.|J Nanobiotechnology. 2025 Aug 26;23 (1) :590.|JCI Insight. 2021 Sep 22;6 (18) :e133690.|Mediators Inflamm. 2019 Oct 7;2019:6168340.|Mediators Inflamm. 2020 Oct 24;2020:1649453.|Microorganisms. 2024 Dec 2;12 (12) :2483.|Microvasc Res. 2023 Jul:148:104531.|Mol Cell Probes. 2023 Feb:67:101896.|Nutrients. 2022 Nov 25;14 (23) :5025.|PeerJ. 2023 May 25:11:e15407.|Peptides. 2024 Dec 5:183:171333.|Phytomedicine. 2022 Sep:104:154242.|Placenta. 2021 Mar:106:30-39.|Placenta. 2022 Jan:117:95-108.|Res Sq. 2025 Nov 12.|Research Square Preprint. 2021 Feb.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 May 30.|Sci Rep. 2025 Oct 31;15 (1) :38208.|Sex Med. 2025 Aug 6;13 (4) :qfaf059.|Signal Transduct Target Ther. 2025 May 28;10 (1) :167.|Toxicol Appl Pharmacol. 2019 Mar 1:366:83-95.|University of Jena. 2023 Dec.|Vet Microbiol. 2022 Sep:272:109514.|Biomed Pharmacother. 2020 Aug;128:110240.|Cell Tissue Res. 2022 Apr;388 (1) :181-194.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6500709-01 0.1 mL
SREBF1, ID (Processed Sterol Regulatory Element-binding Protein 1, Class D Basic Helix-loop-helix Protein 1, bHLHd1, Sterol Regulatory Element-binding Transcription Factor 1, Sterol Regulatory Element-binding Protein 1, SREBP-1, BHLHD1) (MaxLight 750)
Ask
View Details MBS6500709-02 5x 0.1 mL
SREBF1, ID (Processed Sterol Regulatory Element-binding Protein 1, Class D Basic Helix-loop-helix Protein 1, bHLHd1, Sterol Regulatory Element-binding Transcription Factor 1, Sterol Regulatory Element-binding Protein 1, SREBP-1, BHLHD1) (MaxLight 750)
Ask
View Details 